{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,10]],"date-time":"2026-02-10T19:59:54Z","timestamp":1770753594948,"version":"3.50.0"},"reference-count":103,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2023,3,4]],"date-time":"2023-03-04T00:00:00Z","timestamp":1677888000000},"content-version":"vor","delay-in-days":3,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"crossref","award":["R01 AI137080"],"award-info":[{"award-number":["R01 AI137080"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"crossref","award":["RO1 AI137080"],"award-info":[{"award-number":["RO1 AI137080"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"crossref","award":["R01 AI137080"],"award-info":[{"award-number":["R01 AI137080"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"crossref","award":["R01 AI137080"],"award-info":[{"award-number":["R01 AI137080"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100001774","name":"University of Sydney","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100001774","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Pharmacokinet"],"published-print":{"date-parts":[[2023,3]]},"DOI":"10.1007\/s40262-023-01220-y","type":"journal-article","created":{"date-parts":[[2023,3,4]],"date-time":"2023-03-04T02:02:17Z","timestamp":1677895337000},"page":"375-398","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["Alternative Methods for Therapeutic Drug Monitoring and Dose Adjustment of Tuberculosis Treatment in Clinical Settings: A Systematic Review"],"prefix":"10.1007","volume":"62","author":[{"given":"Prakruti S.","family":"Rao","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nisha","family":"Modi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nam-Tien Tran","family":"Nguyen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dinh Hoa","family":"Vu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yingda L.","family":"Xie","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Monica","family":"Gandhi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Roy","family":"Gerona","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John","family":"Metcalfe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Scott K.","family":"Heysell","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6703-0288","authenticated-orcid":false,"given":"Jan-Willem C.","family":"Alffenaar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2023,3,4]]},"reference":[{"key":"1220_CR1","doi-asserted-by":"publisher","first-page":"1464","DOI":"10.1093\/infdis\/jit352","volume":"208","author":"JG Pasipanodya","year":"2013","unstructured":"Pasipanodya JG, McIlleron H, Burger A, Wash PA, Smith P, Gumbo T. Serum drug concentrations predictive of pulmonary tuberculosis outcomes. J Infect Dis. 2013;208:1464\u201373.","journal-title":"J Infect Dis"},{"key":"1220_CR2","doi-asserted-by":"publisher","first-page":"1951","DOI":"10.1093\/infdis\/jir658","volume":"204","author":"S Srivastava","year":"2011","unstructured":"Srivastava S, Pasipanodya JG, Meek C, Leff R, Gumbo T. Multidrug-resistant tuberculosis not due to noncompliance but to between-patient pharmacokinetic variability. J Infect Dis. 2011;204:1951\u20139.","journal-title":"J Infect Dis"},{"key":"1220_CR3","doi-asserted-by":"publisher","first-page":"2101925","DOI":"10.1183\/13993003.01925-2021","volume":"59","author":"X Zheng","year":"2022","unstructured":"Zheng X, Davies Forsman L, Bao Z, Xie Y, Ning Z, Sch\u00f6n T, et al. Drug exposure and susceptibility of second-line drugs correlate with treatment response in patients with multidrug-resistant tuberculosis: a multicentre prospective cohort study in China. Eur Respir J. 2022;59:2101925.","journal-title":"Eur Respir J"},{"key":"1220_CR4","doi-asserted-by":"publisher","first-page":"e3520","DOI":"10.1093\/cid\/ciaa1569","volume":"73","author":"X Zheng","year":"2021","unstructured":"Zheng X, Bao Z, Forsman LD, Hu Y, Ren W, Gao Y, et al. Drug exposure and minimum inhibitory concentration predict pulmonary tuberculosis treatment response. Clin Infect Dis. 2021;73:e3520\u20138.","journal-title":"Clin Infect Dis"},{"key":"1220_CR5","doi-asserted-by":"publisher","first-page":"483","DOI":"10.5588\/ijtld.22.0188","volume":"26","author":"JWC Alffenaar","year":"2022","unstructured":"Alffenaar JWC, Stocker SL, Forsman LD, Garcia-Prats A, Heysell SK, Aarnoutse RE, et al. Clinical standards for the dosing and management of TB drugs. Int J Tuberc Lung Dis. 2022;26:483\u201399.","journal-title":"Int J Tuberc Lung Dis"},{"key":"1220_CR6","doi-asserted-by":"publisher","first-page":"813","DOI":"10.1517\/17425255.2014.895813","volume":"10","author":"J Reynolds","year":"2014","unstructured":"Reynolds J, Heysell SK. Understanding pharmacokinetics to improve tuberculosis treatment outcome. Expert Opin Drug Metab Toxicol. 2014;10:813\u201323.","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"1220_CR7","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1097\/FTD.0000000000000936","volume":"44","author":"HY Kim","year":"2022","unstructured":"Kim HY, Byashalira KC, Heysell SK, M\u00e4rtson A-G, Mpagama SG, Rao P, et al. Therapeutic drug monitoring of anti-infective drugs: implementation strategies for 3 different scenarios. Ther Drug Monit. 2022;44:3\u201310.","journal-title":"Ther Drug Monit"},{"key":"1220_CR8","doi-asserted-by":"crossref","unstructured":"Alffenaar J-WC, Gumbo T, Dooley KE, Peloquin CA, Mcilleron H, Zagorski A, et al. Integrating pharmacokinetics and pharmacodynamics in operational research to end tuberculosis. Clin Infect Dis. 2020;70:1774\u201380.","DOI":"10.1093\/cid\/ciz942"},{"key":"1220_CR9","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1097\/FTD.0000000000000643","volume":"41","author":"S Capiau","year":"2019","unstructured":"Capiau S, Veenhof H, Koster RA, Bergqvist Y, Boettcher M, Halmingh O, et al. Official International Association for Therapeutic Drug Monitoring and Clinical Toxicology guideline: development and validation of dried blood spot-based methods for therapeutic drug monitoring. Ther Drug Monit. 2019;41:409\u201330.","journal-title":"Ther Drug Monit"},{"key":"1220_CR10","doi-asserted-by":"publisher","first-page":"2931","DOI":"10.2174\/138161211797470174","volume":"17","author":"D Vu","year":"2011","unstructured":"Vu D, Alffenaar J, Edelbroek P, Brouwers J, Uges D. Dried blood spots: a new tool for tuberculosis treatment optimization. Curr Pharm Des. 2011;17:2931\u20139.","journal-title":"Curr Pharm Des"},{"key":"1220_CR11","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1186\/s12879-016-1576-1","volume":"16","author":"I Zentner","year":"2016","unstructured":"Zentner I, Schlecht HP, Khensouvann L, Tamuhla N, Kutzler M, Ivaturi V, et al. Urine colorimetry to detect low rifampin exposure during tuberculosis therapy: a proof-of-concept study. BMC Infect Dis. 2016;16:242.","journal-title":"BMC Infect Dis"},{"key":"1220_CR12","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1016\/j.ijid.2017.12.017","volume":"68","author":"I Zentner","year":"2018","unstructured":"Zentner I, Modongo C, Zetola NM, Pasipanodya JG, Srivastava S, Heysell SK, et al. Urine colorimetry for therapeutic drug monitoring of pyrazinamide during tuberculosis treatment. Int J Infect Dis. 2018;68:18\u201323.","journal-title":"Int J Infect Dis"},{"key":"1220_CR13","doi-asserted-by":"crossref","first-page":"411","DOI":"10.4103\/ijmy.ijmy_186_20","volume":"9","author":"P Rao","year":"2020","unstructured":"Rao P, Zhdanova S, Ogarkov O, Orlova E, Ebers A, Stroup S, et al. Urine colorimetry for levofloxacin pharmacokinetics and personalized dosing in people with drug-resistant tuberculosis. Int J Mycobacteriol. 2020;9:411\u20136.","journal-title":"Int J Mycobacteriol."},{"key":"1220_CR14","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0045913","volume":"7","author":"I Nicolau","year":"2012","unstructured":"Nicolau I, Tian L, Menzies D, Ostiguy G, Pai M. Point-of-care urine tests for smoking status and isoniazid treatment monitoring in adult patients. PLoS ONE. 2012;7: e45913.","journal-title":"PLoS ONE"},{"key":"1220_CR15","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1093\/jpids\/piaa024","volume":"10","author":"C Szipszky","year":"2021","unstructured":"Szipszky C, Van Aartsen D, Criddle S, Rao P, Zentner I, Justine M, et al. Determination of rifampin concentrations by urine colorimetry and mobile phone readout for personalized dosing in tuberculosis treatment. J Pediatr Infect Dis Soc. 2021;10:104\u201311.","journal-title":"J Pediatr Infect Dis Soc."},{"key":"1220_CR16","doi-asserted-by":"crossref","unstructured":"Raju KSR, Taneja I, Singh SP, Wahajuddin. Utility of noninvasive biomatrices in pharmacokinetic studies: noninvasive biomatrices in pharmacokinetics. Biomed Chromatogr. 2013;27:1354\u201366.","DOI":"10.1002\/bmc.2996"},{"key":"1220_CR17","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1097\/FTD.0000000000000462","volume":"40","author":"SHJ van den Elsen","year":"2018","unstructured":"van den Elsen SHJ, Oostenbrink LM, Heysell SK, Hira D, Touw DJ, Akkerman OW, et al. Systematic review of salivary versus blood concentrations of antituberculosis drugs and their potential for salivary therapeutic drug monitoring. Ther Drug Monit. 2018;40:17\u201337.","journal-title":"Ther Drug Monit"},{"key":"1220_CR18","doi-asserted-by":"crossref","unstructured":"Alffenaar J-WC, Jongedijk EM, van Winkel CAJ, Sariko M, Heysell SK, Mpagama S, et al. A mobile microvolume UV\/visible light spectrophotometer for the measurement of levofloxacin in saliva. J Antimicrob Chemother. 2021;76:423\u20139.","DOI":"10.1093\/jac\/dkaa420"},{"key":"1220_CR19","doi-asserted-by":"publisher","first-page":"1786","DOI":"10.1093\/jac\/dkab075","volume":"76","author":"HY Kim","year":"2021","unstructured":"Kim HY, Ruiter E, Jongedijk EM, Ak HK, Marais BJ, Pk B, et al. Saliva-based linezolid monitoring on a mobile UV spectrophotometer. J Antimicrob Chemother. 2021;76:1786\u201392.","journal-title":"J Antimicrob Chemother"},{"key":"1220_CR20","doi-asserted-by":"publisher","first-page":"1547","DOI":"10.1093\/jac\/dkab057","volume":"76","author":"S Mohamed","year":"2021","unstructured":"Mohamed S, Mvungi HC, Sariko M, Rao P, Mbelele P, Jongedijk EM, et al. Levofloxacin pharmacokinetics in saliva as measured by a mobile microvolume UV spectrophotometer among people treated for rifampicin-resistant TB in Tanzania. J Antimicrob Chemother. 2021;76:1547\u201352.","journal-title":"J Antimicrob Chemother"},{"key":"1220_CR21","doi-asserted-by":"publisher","first-page":"52","DOI":"10.5588\/ijtld.20.0574","volume":"25","author":"V Mave","year":"2021","unstructured":"Mave V, Kadam D, Gaikwad S, Kinikar A, Aguilar D, Chavan A, et al. Measuring TB drug levels in the hair in adults and children to monitor drug exposure and outcomes. Int J Tuberc Lung Dis. 2021;25:52\u201360.","journal-title":"Int J Tuberc Lung Dis"},{"key":"1220_CR22","doi-asserted-by":"publisher","first-page":"e02145","DOI":"10.1128\/AAC.02145-19","volume":"64","author":"S Wasserman","year":"2020","unstructured":"Wasserman S, Huo S, Ky K, Malig YN, Esmail A, Dheda K, et al. Correlation of linezolid hair concentrations with plasma exposure in patients with drug-resistant tuberculosis. Antimicrob Agents Chemother. 2020;64:e02145-e2219.","journal-title":"Antimicrob Agents Chemother"},{"key":"1220_CR23","doi-asserted-by":"publisher","first-page":"3","DOI":"10.5588\/ijtld.20.0797","volume":"25","author":"JWC Alffenaar","year":"2021","unstructured":"Alffenaar JWC, Marais BJ, Heysell SK. Measuring anti-TB drug concentrations in hair: unlocking the door to cumulative drug exposure and treatment outcome. Int J Tuberc Lung Dis. 2021;25:3\u20135.","journal-title":"Int J Tuberc Lung Dis"},{"key":"1220_CR24","unstructured":"World Health Organization. Meeting report of the WHO expert consultation on drug-resistant tuberculosis treatment outcome definitions, 17\u201319 November 2020. Geneva: World Health Organization; 2021. https:\/\/apps.who.int\/iris\/handle\/10665\/340284. Accessed 13 July 2022."},{"key":"1220_CR25","doi-asserted-by":"crossref","unstructured":"Moher D, Liberati A, Tetzlaff J, Altman DG, PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med. 2009;6:e1000097.","DOI":"10.1371\/journal.pmed.1000097"},{"key":"1220_CR26","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.i4919","volume":"355","author":"JA Sterne","year":"2016","unstructured":"Sterne JA, Hern\u00e1n MA, Reeves BC, Savovi\u0107 J, Berkman ND, Viswanathan M, et al. ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions. BMJ. 2016;355: i4919.","journal-title":"BMJ"},{"key":"1220_CR27","unstructured":"H\u00e9der M. From NASA to EU: the evolution of the TRL scale in Public Sector Innovation. Innov J Public Sect Innov J. 2017;22(2):2\u201322."},{"key":"1220_CR28","doi-asserted-by":"publisher","first-page":"6747","DOI":"10.1128\/AAC.03607-14","volume":"58","author":"TL Parsons","year":"2014","unstructured":"Parsons TL, Marzinke MA, Hoang T, Bliven-Sizemore E, Weiner M, Mac Kenzie WR, et al. Quantification of rifapentine, a potent antituberculosis drug, from dried blood spot samples using liquid chromatographic-tandem mass spectrometric analysis. Antimicrob Agents Chemother. 2014;58:6747\u201357.","journal-title":"Antimicrob Agents Chemother"},{"key":"1220_CR29","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1016\/j.ijantimicag.2018.04.020","volume":"52","author":"LC Martial","year":"2018","unstructured":"Martial LC, Kerkhoff J, Martinez N, Rodr\u00edguez M, Coronel R, Molinas G, et al. Evaluation of dried blood spot sampling for pharmacokinetic research and therapeutic drug monitoring of anti-tuberculosis drugs in children. Int J Antimicrob Agents. 2018;52:109\u201313.","journal-title":"Int J Antimicrob Agents"},{"key":"1220_CR30","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/j.talanta.2013.12.043","volume":"121","author":"DH Vu","year":"2014","unstructured":"Vu DH, Koster RA, Bolhuis MS, Greijdanus B, Altena RV, Nguyen DH, et al. Simultaneous determination of rifampicin, clarithromycin and their metabolites in dried blood spots using LC-MS\/MS. Talanta. 2014;121:9\u201317.","journal-title":"Talanta"},{"key":"1220_CR31","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpba.2020.113821","volume":"195","author":"A Brahmadhi","year":"2021","unstructured":"Brahmadhi A, Chen MX, Wang S-Y, Cho Y-Y, Yu M-C, Lee C-H, et al. Determination of fluoroquinolones in dried plasma spots by using microwave-assisted extraction coupled to ultra-high performance liquid chromatography-tandem mass spectrometry for therapeutic drug monitoring. J Pharm Biomed Anal. 2021;195: 113821.","journal-title":"J Pharm Biomed Anal"},{"key":"1220_CR32","doi-asserted-by":"publisher","first-page":"1063","DOI":"10.1016\/j.jchromb.2011.03.017","volume":"879","author":"DH Vu","year":"2011","unstructured":"Vu DH, Koster RA, Alffenaar JWC, Brouwers JRBJ, Uges DRA. Determination of moxifloxacin in dried blood spots using LC-MS\/MS and the impact of the hematocrit and blood volume. J Chromatogr B Anal Technol Biomed Life Sci. 2011;879:1063\u201370.","journal-title":"J Chromatogr B Anal Technol Biomed Life Sci"},{"key":"1220_CR33","doi-asserted-by":"publisher","first-page":"5758","DOI":"10.1128\/AAC.01054-12","volume":"56","author":"DH Vu","year":"2012","unstructured":"Vu DH, Bolhuis MS, Koster RA, Greijdanus B, de Lange WCM, van Altena R, et al. Dried blood spot analysis for therapeutic drug monitoring of linezolid in patients with multidrug-resistant tuberculosis. Antimicrob Agents Chemother. 2012;56:5758\u201363.","journal-title":"Antimicrob Agents Chemother"},{"key":"1220_CR34","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1016\/j.jchromb.2013.08.003","volume":"936","author":"L Baietto","year":"2013","unstructured":"Baietto L, D\u2019Avolio A, Ariaudo A, Corcione S, Simiele M, Cusato J, et al. Development and validation of a new UPLC-PDA method to quantify linezolid in plasma and in dried plasma spots. J Chromatogr B Anal Technol Biomed Life Sci. 2013;936:42\u20137.","journal-title":"J Chromatogr B Anal Technol Biomed Life Sci"},{"key":"1220_CR35","doi-asserted-by":"publisher","first-page":"882","DOI":"10.1016\/j.clinbiochem.2017.04.010","volume":"50","author":"K Lee","year":"2017","unstructured":"Lee K, Jun S-H, Choi M-S, Song SH, Park JS, Lee JH, et al. Application of the isoniazid assay in dried blood spots using the ultra-performance liquid chromatography-tandem mass spectrometry. Clin Biochem. 2017;50:882\u20135.","journal-title":"Clin Biochem"},{"key":"1220_CR36","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/j.ypmed.2004.04.045","volume":"40","author":"CR Macintyre","year":"2005","unstructured":"Macintyre CR, Goebel K, Brown GV. Patient knows best: blinded assessment of nonadherence with antituberculous therapy by physicians, nurses, and patients compared with urine drug levels. Prev Med. 2005;40:41\u20135.","journal-title":"Prev Med"},{"key":"1220_CR37","first-page":"981","volume":"57","author":"KR Burkhardt","year":"1980","unstructured":"Burkhardt KR, Nel EE. Monitoring regularity of drug intake in tuberculous patients by means of simple urine tests. S Afr Med J. 1980;57:981\u20135.","journal-title":"S Afr Med J"},{"key":"1220_CR38","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1177\/00912700222011184","volume":"42","author":"M Hashiguchi","year":"2002","unstructured":"Hashiguchi M, Ohno K, Sakuma A, Hino F, Tanaka T, Ohtsuji M, et al. A simplified method for detecting isoniazid compliance in patients receiving antituberculosis chemotherapy. J Clin Pharmacol. 2002;42:151\u20136.","journal-title":"J Clin Pharmacol"},{"key":"1220_CR39","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1111\/j.1365-2125.1980.tb01773.x","volume":"10","author":"GA Ellard","year":"1980","unstructured":"Ellard GA, Jenner PJ, Downs PA. An evaluation of the potential use of isoniazid, acetylisoniazid and isonicotinic acid for monitoring the self-administration of drugs. Br J Clin Pharmacol. 1980;10:369\u201381.","journal-title":"Br J Clin Pharmacol"},{"key":"1220_CR40","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1186\/s12951-015-0105-5","volume":"13","author":"K Chatterjee","year":"2015","unstructured":"Chatterjee K, Kuo CW, Chen A, Chen P. Detection of residual rifampicin in urine via fluorescence quenching of gold nanoclusters on paper. J Nanobiotechnology. 2015;13:46.","journal-title":"J Nanobiotechnology."},{"key":"1220_CR41","first-page":"738","volume":"100","author":"L Eidus","year":"1969","unstructured":"Eidus L, Harnanansingh AM. Simple procedures for checking rifampin in urine. Am Rev Respir Dis. 1969;100:738\u20139.","journal-title":"Am Rev Respir Dis"},{"key":"1220_CR42","doi-asserted-by":"crossref","unstructured":"Espinosa-Mansilla A, Acedo-Valenzuela MI, Mu\u00f1oz de la Pe\u00f1a A, Ca\u00f1ada Ca\u00f1ada F, Salinas L\u00f3pez F. Determination of antitubercular drugs in urine and pharmaceuticals by LC using a gradient flow combined with programmed diode array photometric detection. Talanta. 2002;58:273\u201380.","DOI":"10.1016\/S0039-9140(02)00240-0"},{"key":"1220_CR43","first-page":"903","volume":"6","author":"PE Meissner","year":"2002","unstructured":"Meissner PE, Musoke P, Okwera A, Bunn JEG, Coulter JBS. The value of urine testing for verifying adherence to anti-tuberculosis chemotherapy in children and adults in Uganda. Int J Tuberc Lung Dis. 2002;6:903\u20138.","journal-title":"Int J Tuberc Lung Dis"},{"key":"1220_CR44","doi-asserted-by":"publisher","first-page":"300","DOI":"10.1016\/0041-3879(70)90023-1","volume":"51","author":"DA Mitchison","year":"1970","unstructured":"Mitchison DA, Allen BW, Miller AB. Detection of rifampicin in urine by a simple microbiological assay. Tubercle. 1970;51:300\u20134.","journal-title":"Tubercle"},{"key":"1220_CR45","first-page":"1517","volume":"87","author":"NP Mqoqi","year":"1997","unstructured":"Mqoqi NP, Churchyard GA, Kleinschmidt I, Williams B. Attendance versus compliance with tuberculosis treatment in an occupational setting: a pilot study. S Afr Med J. 1997;87:1517\u201321.","journal-title":"S Afr Med J"},{"key":"1220_CR46","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1002\/ppul.10314","volume":"36","author":"A Palanduz","year":"2003","unstructured":"Palanduz A, Gultekin D, Kayaalp N. Follow-up of compliance with tuberculosis treatment in children: monitoring by urine tests. Pediatr Pulmonol. 2003;36:55\u20137.","journal-title":"Pediatr Pulmonol"},{"key":"1220_CR47","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1016\/j.ijpharm.2005.09.033","volume":"307","author":"FA Sirgel","year":"2006","unstructured":"Sirgel FA, Maritz JS, Venter A, Langdon G, Smith PJ, Donald PR. Monitoring the ingestion of anti-tuberculosis drugs by simple non-invasive methods. Int J Pharm. 2006;307:182\u20137.","journal-title":"Int J Pharm"},{"key":"1220_CR48","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1016\/0007-0971(88)90070-8","volume":"82","author":"AG Wardman","year":"1988","unstructured":"Wardman AG, Knox AJ, Muers MF, Page RL. Profiles of non-compliance with antituberculous therapy. Br J Dis Chest. 1988;82:285\u20139.","journal-title":"Br J Dis Chest"},{"key":"1220_CR49","doi-asserted-by":"publisher","first-page":"528","DOI":"10.5588\/ijtld.13.0730","volume":"18","author":"V Amlabu","year":"2014","unstructured":"Amlabu V, Mulligan C, Jele N, Evans A, Gray D, Zar HJ, et al. Isoniazid\/acetylisoniazid urine concentrations: markers of adherence to isoniazid preventive therapy in children. Int J Tuberc Lung Dis. 2014;18:528\u201330.","journal-title":"Int J Tuberc Lung Dis"},{"key":"1220_CR50","doi-asserted-by":"publisher","first-page":"e397","DOI":"10.1097\/MJT.0000000000000032","volume":"25","author":"CA Anusiem","year":"2018","unstructured":"Anusiem CA, Brown SA, Ezejiofor NA, Barikpoar E, Orisakwe OE. Isoniazid pharmacokinetics in the presence of ofloxacin and norfloxacin antibiotics. Am J Ther. 2018;25:e397-404.","journal-title":"Am J Ther"},{"key":"1220_CR51","doi-asserted-by":"publisher","first-page":"736","DOI":"10.1378\/chest.123.3.736","volume":"123","author":"T Eidlitz-Markus","year":"2003","unstructured":"Eidlitz-Markus T, Zeharia A, Baum G, Mimouni M, Amir J. Use of the urine color test to monitor compliance with isoniazid treatment of latent tuberculosis infection. Chest. 2003;123:736\u20139.","journal-title":"Chest"},{"key":"1220_CR52","doi-asserted-by":"publisher","first-page":"1225","DOI":"10.1016\/S0140-6736(05)63457-5","volume":"350","author":"J Elizaga","year":"1997","unstructured":"Elizaga J, Friedland JS. Monitoring compliance with antituberculous treatment by detection of isoniazid in urine. Lancet. 1997;350:1225\u20136.","journal-title":"Lancet"},{"key":"1220_CR53","doi-asserted-by":"publisher","first-page":"754","DOI":"10.1016\/j.rmed.2010.02.001","volume":"104","author":"RL Guerra","year":"2010","unstructured":"Guerra RL, Conde MB, Efron A, Loredo C, Bastos G, Chaisson RE, et al. Point-of-care Arkansas method for measuring adherence to treatment with isoniazid. Respir Med. 2010;104:754\u20137.","journal-title":"Respir Med"},{"key":"1220_CR54","first-page":"695","volume":"90","author":"EJ Hamilton","year":"1964","unstructured":"Hamilton EJ, Jessamine AG, Eidus L. Specificity of the isoniazid drop test for control of domiciliary treatment of tuberculosis. Can Med Assoc J. 1964;90:695\u20137.","journal-title":"Can Med Assoc J"},{"key":"1220_CR55","first-page":"1232","volume":"11","author":"Y Hanifa","year":"2007","unstructured":"Hanifa Y, Mngadi K, Lewis J, Fielding K, Churchyard G, Grant AD. Evaluation of the Arkansas method of urine testing for isoniazid in South Africa. Int J Tuberc Lung Dis. 2007;11:1232\u20136.","journal-title":"Int J Tuberc Lung Dis"},{"key":"1220_CR56","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1097\/QAD.0000000000002380","volume":"34","author":"EA Kendall","year":"2020","unstructured":"Kendall EA, Durovni B, Martinson NA, Cavalacante S, Masonoke K, Saraceni V, et al. Adherence to tuberculosis preventive therapy measured by urine metabolite testing among people with HIV. AIDS. 2020;34:63\u201371.","journal-title":"AIDS"},{"key":"1220_CR57","doi-asserted-by":"publisher","first-page":"e43","DOI":"10.1097\/INF.0000000000002936","volume":"40","author":"SM LaCourse","year":"2021","unstructured":"LaCourse SM, Leon D, Panpradist N, Richardson BA, Maleche-Obimbo E, Mecha J, et al. Urine biomarker assessment of infant adherence to isoniazid prophylaxis. Pediatr Infect Dis J. 2021;40:e43\u20135.","journal-title":"Pediatr Infect Dis J"},{"key":"1220_CR58","first-page":"847","volume":"36","author":"DM Macfadyen","year":"1967","unstructured":"Macfadyen DM, Heffernan JF. Urine testing for isoniazid in the supervision of out-patient oral chemotherapy for pulmonary tuberculosis: the failure of a routine service. Bull World Health Organ. 1967;36:847\u201352.","journal-title":"Bull World Health Organ"},{"key":"1220_CR59","doi-asserted-by":"publisher","first-page":"107","DOI":"10.3390\/antibiotics7040107","volume":"7","author":"P Mishra","year":"2018","unstructured":"Mishra P, Albiol-Chiva J, Bose D, Durgbanshi A, Peris-Vicente J, Carda-Broch S, et al. Optimization and validation of a chromatographic method for the quantification of isoniazid in urine of tuberculosis patients according to the European Medicines Agency guideline. Antibiotics (Basel). 2018;7:107.","journal-title":"Antibiotics (Basel)."},{"key":"1220_CR60","first-page":"122","volume":"104","author":"R Narain","year":"1971","unstructured":"Narain R, Rao MS, Naganna K, Bagga AS. Estimating the population consuming isoniazid by urine test. Am Rev Respir Dis. 1971;104:122\u20135.","journal-title":"Am Rev Respir Dis"},{"key":"1220_CR61","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1016\/S0895-4356(01)00470-X","volume":"55","author":"S Perry","year":"2002","unstructured":"Perry S, Hovell MF, Blumberg E, Berg J, Vera A, Sipan C, et al. Urine testing to monitor adherence to TB preventive therapy. J Clin Epidemiol. 2002;55:235\u20138.","journal-title":"J Clin Epidemiol"},{"key":"1220_CR62","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1177\/1054773810363473","volume":"19","author":"KE Schmitz","year":"2010","unstructured":"Schmitz KE, Hovell MF, Wong CA, Kelley NJ, Nilsen D, Blumberg EJ, et al. The reliability and practicality of the Arkansas method assay of isoniazid adherence. Clin Nurs Res. 2010;19:131\u201343.","journal-title":"Clin Nurs Res"},{"key":"1220_CR63","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1378\/chest.98.2.314","volume":"98","author":"DE Schraufnagel","year":"1990","unstructured":"Schraufnagel DE, Stoner R, Whiting E, Snukst-Torbeck G, Werhane MJ. Testing for isoniazid: an evaluation of the Arkansas method. Chest. 1990;98:314\u20136.","journal-title":"Chest"},{"key":"1220_CR64","doi-asserted-by":"publisher","first-page":"1519","DOI":"10.1183\/09031936.00132613","volume":"43","author":"MR Soobratty","year":"2014","unstructured":"Soobratty MR, Whitfield R, Subramaniam K, Grove G, Carver A, O\u2019Donovan GV, et al. Point-of-care urine test for assessing adherence to isoniazid treatment for tuberculosis. Eur Respir J. 2014;43:1519\u201322.","journal-title":"Eur Respir J"},{"key":"1220_CR65","doi-asserted-by":"crossref","unstructured":"Subbaraman R, Thomas BE, Kumar JV, Thiruvengadam K, Khandewale A, Kokila S, et al. Understanding nonadherence to tuberculosis medications in India using urine drug metabolite testing: a cohort study. Open Forum Infect Dis. 2021;8:ofab190.","DOI":"10.1093\/ofid\/ofab190"},{"key":"1220_CR66","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1186\/1471-2334-6-97","volume":"6","author":"TA Szakacs","year":"2006","unstructured":"Szakacs TA, Wilson D, Cameron DW, Clark M, Kocheleff P, Muller FJ, et al. Adherence with isoniazid for prevention of tuberculosis among HIV-infected adults in South Africa. BMC Infect Dis. 2006;6:97.","journal-title":"BMC Infect Dis"},{"key":"1220_CR67","first-page":"277","volume":"3","author":"VM Venho","year":"1971","unstructured":"Venho VM, Koskinen R. The effect of pyrazinamide, rifampicin and cycloserine on the blood levels and urinary excretion of isoniazid. Ann Clin Res. 1971;3:277\u201380.","journal-title":"Ann Clin Res"},{"key":"1220_CR68","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1258\/0004563041731637","volume":"41","author":"R Whitfield","year":"2004","unstructured":"Whitfield R, Cope GF. Point-of-care test to monitor adherence to anti-tuberculous treatment. Ann Clin Biochem. 2004;41:411\u20133.","journal-title":"Ann Clin Biochem"},{"key":"1220_CR69","doi-asserted-by":"publisher","DOI":"10.1016\/j.colsurfb.2021.111627","volume":"201","author":"Y Zhao","year":"2021","unstructured":"Zhao Y, Zhang X, Jia C, Wu J, Tang H, Shang J, et al. A simple signal-on strategy for fluorescent detection of tuberculostatic drug isoniazid based on Ag clusters-MnO(2) sheets nanoplatform. Colloids Surf B Biointerfaces. 2021;201: 111627.","journal-title":"Colloids Surf B Biointerfaces"},{"key":"1220_CR70","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1016\/S0041-3879(64)80075-1","volume":"45","author":"A Pines","year":"1964","unstructured":"Pines A, Richardson RJ. A simple table test for the detection of pyrazinamide in the urine. Tubercle. 1964;45:166\u20138.","journal-title":"Tubercle"},{"key":"1220_CR71","first-page":"291","volume":"50","author":"MJ Mattila","year":"1969","unstructured":"Mattila MJ, Nieminen E, Tiitinen H. Serum levels, urinary excretion, and side-effects of cycloserine in the presence of isoniazid and p-aminosalicylic acid. Scand J Respir Dis. 1969;50:291\u2013300.","journal-title":"Scand J Respir Dis."},{"key":"1220_CR72","first-page":"315","volume":"98","author":"L Eidus","year":"1968","unstructured":"Eidus L, Harnanansingh AM. A urine test for control of ingestion of ethionamide. Am Rev Respir Dis. 1968;98:315\u20136.","journal-title":"Am Rev Respir Dis"},{"key":"1220_CR73","first-page":"413","volume":"99","author":"L Eidus","year":"1968","unstructured":"Eidus L, Jessamine AG, Harnanansingh AM. Evaluation of a urinary colour test in the surveillance of ethionamide medication. Can Med Assoc J. 1968;99:413\u20135.","journal-title":"Can Med Assoc J"},{"key":"1220_CR74","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/0041-3879(90)90057-F","volume":"71","author":"P Gurumurthy","year":"1990","unstructured":"Gurumurthy P, Rahman F, Narayana AS, Sarma GR. Salivary levels of isoniazid and rifampicin in tuberculous patients. Tubercle. 1990;71:29\u201333.","journal-title":"Tubercle"},{"key":"1220_CR75","doi-asserted-by":"publisher","first-page":"3663","DOI":"10.1016\/j.jchromb.2011.09.047","volume":"879","author":"AKH Kumar","year":"2011","unstructured":"Kumar AKH, Sudha V, Srinivasan R, Ramachandran G. Simple and rapid liquid chromatography method for determination of moxifloxacin in saliva. J Chromatogr B Anal Technol Biomed Life Sci. 2011;879:3663\u20137.","journal-title":"J Chromatogr B Anal Technol Biomed Life Sci"},{"key":"1220_CR76","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1097\/00045391-200007050-00008","volume":"7","author":"SI Ofoefule","year":"2000","unstructured":"Ofoefule SI, Onyeagba OE, Orisakwe OE. Effects of pefloxacin on urinary and salivary concentrations of isoniazid in six healthy female volunteers. Am J Ther. 2000;7:313\u20136.","journal-title":"Am J Ther"},{"key":"1220_CR77","doi-asserted-by":"publisher","first-page":"2000803","DOI":"10.1183\/13993003.00803-2020","volume":"56","author":"SHJ van den Elsen","year":"2020","unstructured":"van den Elsen SHJ, Akkerman OW, Wessels M, Jongedijk EM, Ghimire S, van der Werf TS, et al. Dose optimisation of first-line tuberculosis drugs using therapeutic drug monitoring in saliva: feasible for rifampicin, not for isoniazid. Eur Respir J. 2020;56:2000803.","journal-title":"Eur Respir J"},{"key":"1220_CR78","doi-asserted-by":"publisher","first-page":"1901903","DOI":"10.1183\/13993003.01903-2019","volume":"55","author":"SHJ van den Elsen","year":"2020","unstructured":"van den Elsen SHJ, Akkerman OW, Jongedijk EM, Wessels M, Ghimire S, van der Werf TS, et al. Therapeutic drug monitoring using saliva as matrix: an opportunity for linezolid, but challenge for moxifloxacin. Eur Respir J. 2020;55:1901903.","journal-title":"Eur Respir J"},{"key":"1220_CR79","doi-asserted-by":"publisher","first-page":"e02379","DOI":"10.1128\/AAC.02379-18","volume":"63","author":"S Ghimire","year":"2019","unstructured":"Ghimire S, Maharjan B, Jongedijk EM, Kosterink JGW, Ghimire GR, Touw DJ, et al. Evaluation of saliva as a potential alternative sampling matrix for therapeutic drug monitoring of levofloxacin in patients with multidrug-resistant tuberculosis. Antimicrob Agents Chemother. 2019;63:e02379-e2418.","journal-title":"Antimicrob Agents Chemother"},{"key":"1220_CR80","doi-asserted-by":"publisher","first-page":"3676","DOI":"10.1128\/AAC.00558-13","volume":"57","author":"MS Bolhuis","year":"2013","unstructured":"Bolhuis MS, van Altena R, van Hateren K, de Lange WCM, Greijdanus B, Uges DRA, et al. Clinical validation of the analysis of linezolid and clarithromycin in oral fluid of patients with multidrug-resistant tuberculosis. Antimicrob Agents Chemother. 2013;57:3676\u201380.","journal-title":"Antimicrob Agents Chemother"},{"key":"1220_CR81","doi-asserted-by":"publisher","first-page":"1702024","DOI":"10.1183\/13993003.02024-2017","volume":"51","author":"SHJ van den Elsen","year":"2018","unstructured":"van den Elsen SHJ, Akkerman OW, Huisman JR, Touw DJ, van der Werf TS, Bolhuis MS, et al. Lack of penetration of amikacin into saliva of tuberculosis patients. Eur Respir J. 2018;51:1702024.","journal-title":"Eur Respir J"},{"key":"1220_CR82","volume":"2012","author":"M Eisenhut","year":"2012","unstructured":"Eisenhut M, Thieme D, Schmid D, Fieseler S, Sachs H. Hair Analysis for determination of isoniazid concentrations and acetylator phenotype during antituberculous treatment. Tuberc Res Treat. 2012;2012: 327027.","journal-title":"Tuberc Res Treat."},{"key":"1220_CR83","doi-asserted-by":"publisher","DOI":"10.1016\/j.jchromb.2020.122467","volume":"1169","author":"A Reckers","year":"2021","unstructured":"Reckers A, Huo S, Esmail A, Dheda K, Bacchetti P, Gandhi M, et al. Development and validation of a liquid chromatography-tandem mass spectrometry method for quantifying delamanid and its metabolite in small hair samples. J Chromatogr B Analyt Technol Biomed Life Sci. 2021;1169: 122467.","journal-title":"J Chromatogr B Analyt Technol Biomed Life Sci"},{"key":"1220_CR84","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0189101","volume":"12","author":"V Mave","year":"2017","unstructured":"Mave V, Kinikar A, Kagal A, Nimkar S, Koli H, Khwaja S, et al. Isoniazid concentrations in hair and plasma area-under-the-curve exposure among children with tuberculosis. PLoS ONE. 2017;12: e0189101.","journal-title":"PLoS ONE"},{"key":"1220_CR85","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1186\/s12879-020-05738-5","volume":"21","author":"J Metcalfe","year":"2021","unstructured":"Metcalfe J, Bacchetti P, Esmail A, Reckers A, Aguilar D, Wen A, et al. Diagnostic accuracy of a liquid chromatography-tandem mass spectrometry assay in small hair samples for rifampin-resistant tuberculosis drug concentrations in a routine care setting. BMC Infect Dis. 2021;21:99.","journal-title":"BMC Infect Dis"},{"key":"1220_CR86","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0155887","volume":"11","author":"R Gerona","year":"2016","unstructured":"Gerona R, Wen A, Chin AT, Koss CA, Bacchetti P, Metcalfe J, et al. Quantifying isoniazid levels in small hair samples: a novel method for assessing adherence during the treatment of latent and active tuberculosis. PLoS ONE. 2016;11: e0155887.","journal-title":"PLoS ONE"},{"key":"1220_CR87","doi-asserted-by":"publisher","first-page":"991","DOI":"10.5588\/ijtld.16.0201","volume":"20","author":"R Gerona","year":"2016","unstructured":"Gerona R, Wen A, Koss C, Bacchetti P, Gandhi M, Metcalfe J. A multi-analyte panel for non-invasive pharmacokinetic monitoring of second-line anti-tuberculosis drugs. Int J Tuberc Lung Dis. 2016;20:991\u20132.","journal-title":"Int J Tuberc Lung Dis"},{"key":"1220_CR88","doi-asserted-by":"publisher","DOI":"10.1016\/j.jchromb.2019.121729","volume":"1125","author":"R Gerona","year":"2019","unstructured":"Gerona R, Wen A, Aguilar D, Shum J, Reckers A, Bacchetti P, et al. Simultaneous analysis of 11 medications for drug resistant TB in small hair samples to quantify adherence and exposure using a validated LC-MS\/MS panel. J Chromatogr B Anal Technol Biomed Life Sci. 2019;1125: 121729.","journal-title":"J Chromatogr B Anal Technol Biomed Life Sci"},{"key":"1220_CR89","doi-asserted-by":"publisher","first-page":"844","DOI":"10.5588\/ijtld.15.0882","volume":"20","author":"V Mave","year":"2016","unstructured":"Mave V, Chandanwale A, Kinikar A, Khadse S, Kagal A, Gupte N, et al. Isoniazid hair concentrations in children with tuberculosis: a proof of concept study. Int J Tuberc Lung Dis. 2016;20:844\u20137.","journal-title":"Int J Tuberc Lung Dis"},{"key":"1220_CR90","doi-asserted-by":"publisher","first-page":"00046","DOI":"10.1183\/23120541.00046-2019","volume":"5","author":"J Metcalfe","year":"2019","unstructured":"Metcalfe J, Bacchetti P, Gerona R, Esmail A, Dheda K, Gandhi M. Association of anti-tuberculosis drug concentrations in hair and treatment outcomes in MDR- and XDR-TB. ERJ Open Res. 2019;5:00046\u20132019.","journal-title":"ERJ Open Res."},{"key":"1220_CR91","doi-asserted-by":"publisher","first-page":"1069","DOI":"10.5588\/ijtld.17.0408","volume":"21","author":"J Metcalfe","year":"2017","unstructured":"Metcalfe J, Gerona R, Wen A, Bacchetti P, Gandhi M. An LC-MS\/MS-based method to analyze the anti-tuberculosis drug bedaquiline in hair. Int J Tuberc Lung Dis. 2017;21:1069\u201370.","journal-title":"Int J Tuberc Lung Dis"},{"key":"1220_CR92","doi-asserted-by":"publisher","unstructured":"Reckers A, Wen A, Aguilar D, Bacchetti P, Gandhi M, Metcalfe J, et al. Validated LC-MS\/MS panel for quantifying 11 drug-resistant TB medications in small hair samples. J Vis Exp. 2020. https:\/\/doi.org\/10.3791\/60861.","DOI":"10.3791\/60861"},{"key":"1220_CR93","doi-asserted-by":"publisher","first-page":"4605","DOI":"10.1128\/AAC.00177-10","volume":"54","author":"F Pea","year":"2010","unstructured":"Pea F, Furlanut M, Cojutti P, Cristini F, Zamparini E, Franceschi L, et al. Therapeutic drug monitoring of linezolid: a retrospective monocentric analysis. Antimicrob Agents Chemother. 2010;54:4605\u201310.","journal-title":"Antimicrob Agents Chemother"},{"key":"1220_CR94","volume-title":"Rapid communication: key changes to the treatment of drug-resistant tuberculosis","author":"World Health Organization","year":"2022","unstructured":"World Health Organization. Rapid communication: key changes to the treatment of drug-resistant tuberculosis. Geneva: World Health Organization; 2022."},{"key":"1220_CR95","doi-asserted-by":"publisher","first-page":"714","DOI":"10.1097\/FTD.0000000000000659","volume":"41","author":"MA Zuur","year":"2019","unstructured":"Zuur MA, Veenhof H, Aleksa A, Van\u02bctBoveneind-Vrubleuskaya N, Darmawan E, Hasnain MG, et al. Quality assessment of dried blood spots from patients with tuberculosis from 4 countries. Ther Drug Monit. 2019;41:714\u20138.","journal-title":"Ther Drug Monit"},{"key":"1220_CR96","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1093\/cid\/cis353","volume":"55","author":"JG Pasipanodya","year":"2012","unstructured":"Pasipanodya JG, Srivastava S, Gumbo T. Meta-analysis of clinical studies supports the pharmacokinetic variability hypothesis for acquired drug resistance and failure of antituberculosis therapy. Clin Infect Dis. 2012;55:169\u201377.","journal-title":"Clin Infect Dis"},{"key":"1220_CR97","doi-asserted-by":"publisher","first-page":"430","DOI":"10.5588\/ijtld.15.0360","volume":"20","author":"MR O\u2019Donnell","year":"2016","unstructured":"O\u2019Donnell MR, Daftary A, Frick M, Hirsch-Moverman Y, Amico KR, Senthilingam M, et al. Re-inventing adherence: toward a patient-centered model of care for drug-resistant tuberculosis and HIV. Int J Tuberc Lung Dis. 2016;20:430\u20134.","journal-title":"Int J Tuberc Lung Dis"},{"key":"1220_CR98","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1007\/BF00548590","volume":"19","author":"TE Sand","year":"1981","unstructured":"Sand TE, Jacobsen S. Effect of urine pH and flow on renal clearance of methotrexate. Eur J Clin Pharmacol. 1981;19:453\u20136.","journal-title":"Eur J Clin Pharmacol"},{"key":"1220_CR99","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1007\/BF00558209","volume":"7","author":"G Boman","year":"1974","unstructured":"Boman G, Ringberger VA. Binding of rifampicin by human plasma proteins. Eur J Clin Pharmacol. 1974;7:369\u201373.","journal-title":"Eur J Clin Pharmacol"},{"key":"1220_CR100","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1007\/BF01059476","volume":"3","author":"HG Boxenbaum","year":"1975","unstructured":"Boxenbaum HG, Berkersky I, Mattaliano V, Kaplan SA. Plasma and salivary concentrations of isoniazid in man: preliminary findings in two slow acetylator subjects. J Pharmacokinet Biopharm. 1975;3:443\u201356.","journal-title":"J Pharmacokinet Biopharm"},{"key":"1220_CR101","doi-asserted-by":"crossref","unstructured":"Alffenaar J-WC, de Steenwinkel JEM, Diacon AH, Simonsson USH, Srivastava S, Wicha SG. Pharmacokinetics and pharmacodynamics of anti-tuberculosis drugs: an evaluation of in vitro, in vivo methodologies and human studies. Front Pharmacol. 2022;13:1063453.","DOI":"10.3389\/fphar.2022.1063453"},{"key":"1220_CR102","doi-asserted-by":"crossref","unstructured":"Touw DJ, Neef C, Thomson AH, Vinks AA. Cost-effectiveness of Therapeutic Drug Monitoring Committee of the International Association for Therapeutic Drug Monitoring and Clinical Toxicology. Cost-effectiveness of therapeutic drug monitoring: a systematic review. Ther Drug Monit. 2005;27:10\u20137.","DOI":"10.1097\/00007691-200502000-00004"},{"key":"1220_CR103","doi-asserted-by":"publisher","first-page":"2102787","DOI":"10.1183\/13993003.02787-2021","volume":"59","author":"I Margineanu","year":"2022","unstructured":"Margineanu I, Akkerman O, Cattaneo D, Goletti D, Marriott DJE, Migliori GB, et al. Practices of therapeutic drug monitoring in tuberculosis: an international survey. Eur Respir J. 2022;59:2102787.","journal-title":"Eur Respir J"}],"container-title":["Clinical Pharmacokinetics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40262-023-01220-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40262-023-01220-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40262-023-01220-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,12,8]],"date-time":"2023-12-08T07:47:51Z","timestamp":1702021671000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40262-023-01220-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3]]},"references-count":103,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2023,3]]}},"alternative-id":["1220"],"URL":"https:\/\/doi.org\/10.1007\/s40262-023-01220-y","relation":{},"ISSN":["0312-5963","1179-1926"],"issn-type":[{"value":"0312-5963","type":"print"},{"value":"1179-1926","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,3]]},"assertion":[{"value":"6 February 2023","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 March 2023","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Open Access funding enabled and organized by CAUL and its Member Institutions. Prakruti S. Rao, Nisha Modi, Yingda L. Xie, and Scott K. Heysell were supported by the National Institutes of Health grant R01 AI137080.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Prakruti S. Rao, Nisha Modi, Nam-Tien Tran Nguyen, Dinh Hoa Vu, Yingda L. Xie, Monica Gandhi, Roy Gerona, John Metcalfe, Scott K. Heysell, and Jan-Willem C. Alffenaar have no conflicts of interest that are directly relevant to the content of this article.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Data used in this study were collected according to the principles of Declaration of Helsinki. Approval was granted by institutional review boards or independent ethics committees for each study from which data were used in this manuscript.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Not applicable.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of data and material"}},{"value":"Not applicable.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}},{"value":"Conceptualization: JWA, SKH. Data extraction and assembling first draft: PSR. All authors contributed to the preparation and critical revision of the manuscript.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Authors\u2019 contributions"}}]}}